You just read:

DIFICLIR[TM] (fidaxomicin) is More Cost Effective Than Current Standard of Care in Cancer Patients, a Vulnerable Population at High Risk of Clostridium Difficile Infection

News provided by

Astellas Pharma EMEA

07 Sep, 2014, 08:00 BST